Recently, antibodies and synthetic small interfering RNA (siRNA) targeting the serine-protease proprotein convertase subtilisin–kexin type-9 (PCSK9), a physiological regulator of LDL-C, have increasingly been used in patients with high ASCVD risk and brought about a further effective decline of LDL-C concentrations with good security [34, 35]. The gene discussed is COG2; the disease is atherosclerosis.